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Background: Bacterial and fungal infections are common and often contribute to death
in patients undergoing extracorporeal membrane oxygenation (ECMO). Drug disposition
is altered during ECMO, and adsorption in the circuit is an established causative factor.
Vancomycin and voriconazole are widely used, despite the lack of evidence-based
prescription guidelines.
Objective: The objective of this study was to determine the extraction of voriconazole
and vancomycin by the Xenios/Novalung ECMO circuits.
Methods: We have set up nine closed-loop ECMO circuits, consisting of four different
iLAActivve® kits for neonatal, pediatric, and adult support: three iLA-ActivveMiniLung®
petite kits, two iLA-ActivveMiniLung® kits, two iLA-ActivveiLA® kits, and two iLA-Activve
X-lung® kits. The circuits were primed with whole blood and maintained at physiologic
conditions for 24 h. Voriconazole and vancomycin were injected as a single-bolus
age-related dose into the circuits. Pre-membrane (P2) blood samples were obtained at
baseline and after drug injection at 2, 10, 30, 180, 360min, and 24 h. A control sample
at 2min was collected for spontaneous drug degradation testing at 24 h.
Results: Seventy-two samples were analyzed in triplicate. The mean percentage of drug
recovery at 24 h was 20% for voriconazole and 62% for vancomycin.
Conclusions: The extraction of voriconazole and vancomycin by contemporary ECMO
circuits is clinically relevant across all age-related circuit sizes and may result in reduced
drug exposure in vivo.
Keywords: extracorporeal membrane oxygenation, pharmacokinetics, pharmacology, antibiotics, infection,
antifungals, drug disposition
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INTRODUCTION
Critically ill patients on extracorporeal membrane oxygenation
(ECMO) are at high risk of serious infections, with rates of 15.4
per 1,000 ECMO days across all age groups (1). As the mortality
of ECMO patients facing an infective event increases up to 68%, a
timely and adequate antimicrobial therapy is essential to improve
outcomes (1–3).
Vancomycin is widely used as the first-line treatment for both
the empiric and targeted treatment of blood stream infections
caused by methicillin-resistant Staphylococcus aureus (MRSA),
coagulase-negative staphylococci (CONS), and ampicillin-
resistant enterococci (1, 4–6). Although bacteria remain the most
common causative agents, fungi contribute to the healthcare
burden being the second cause of nosocomial infection during
ECMO (1), with a prevalence ranging from 0.04 to 5%, and
differences based upon age and timing of infection (2, 5).
Voriconazole is a second-generation triazole and a synthetic
derivative of fluconazole, acting against Candida and Aspergillus
spp., which are the most frequently isolated fungi in ICU (7).
Indeed, the azole class is pivotal in the prevention and treatment
of invasive fungal infections in critically ill patients (7, 8). While
the pharmacology of fluconazole, which is the recommended
first-line treatment against Candida spp., has been extensively
addressed in the pediatric ECMO population (9–11), scanty
evidence is available for voriconazole, a first-line treatment for
invasive aspergillosis (7, 12, 13).
Besides the choice of the proper agent, the selection of the
right dose to attain target exposure is crucial for therapeutic
success (14). Drug dosing is known to be complex in critically
ill patients, and it is further complicated in specific populations,
in which pathology-related factors sum up to physiologic age-
specific PK changes (15). The need for an extracorporeal support
adds interfering mechanisms, which are responsible for further
PK variability (16).
ECMO is increasingly spreading, especially across adult
intensive care settings, to support potentially reversible cardiac or
respiratory failure, unresponsive to conventional treatment (17).
This procedure requires the addition of fluids and exogenous
blood products to prime the circuit, thereby increasing the
circulating volume. As a consequence of hemodilution, priming
compositions, and organ dysfunction, both the volume of
distribution (Vd) and clearance (Cl) of drugs are altered (18).
A certain degree of sequestration into the circuit may be
expected based on the physicochemical characteristics of a
drug, such as molecular size, plasma protein binding, degree
of ionization at physiological pH, and lipophilicity, as all are
based on the characteristics of the circuits and oxygenators (18–
21). Moreover, the exposure of blood to the exogenous surface
triggers a systemic inflammatory response, further contributing
to altered antimicrobial disposition and overall therapeutic
efficacy (16, 20, 22).
Despite the wide use of antimicrobial agents during ECMO
(23), PK data related to newer systems are limited and
heterogeneous, resulting in a poor level of evidence-based
pharmacotherapy (22, 24). Previous pharmacological knowledge
(25–27) needs to be updated according to the recent advances
of extracorporeal technology to prevent altered antimicrobial
exposure during ECMO. Furthermore, the optimization of
pharmacotherapy is required to limit the burden of microbial
resistance (28, 29).
The aim of this study was to provide new insights into the
disposition of voriconazole and vancomycin in contemporary
neonatal, pediatric, and adult ECMO circuits.
MATERIALS AND METHODS
The study was carried out at the Intensive Care Unit of the
Sophia Children’s Hospital—ECMO Center, Erasmus MC in
Rotterdam, the Netherlands. The need for the institutional review
board approval was waived as ethical approval was not required,
according to the Dutch Law of research on human subjects. In
particular, the fact that no patients were used in this in vitro
study determined this decision. Study circuits were provided by
the Xenios R© company as part of an unrestricted research grant.
In vitro ECMO Model
The in vitro ECMO model has been previously published (28).
Here, we present a brief overview of the setting. We have set
up nine different in vitro ECMO circuits, consisting of four
iLAActivve R© kits: iLA-ActivveMiniLung R© petite kits (n = 3),
iLA-ActivveMiniLung R© kits (n = 2), iLA-ActivveiLA R© kits (n
= 2), and iLA-Activve X-lung R© kits (n = 2). They were made
up of hollow fiber oxygenators with a diffusion membrane
for neonatal, pediatric, and adult patients. All circuits were
whole blood primed, connected to a 100-ml reservoir bag and
run for 24 h at a flow rate of 500 ml/min (neonatal), 700
ml/min (infant), 2.5 L/min (pediatric), and 3.5 L/min (adult)
with an estimated circuit volume of 225, 280, 360, and 400ml,
respectively. Anticoagulation was provided by administering a
bolus of heparin 500 UI to maintain activated clotting times over
200 s. Experimental conditions (temperature, pH, hematocrit)
have been maintained stable throughout the study period, as
previously described (30).
Drug Selection and Administration
We selected voriconazole and vancomycin for their clinical
relevance in the Intensive Care Unit (ICU) practice and as
illustrative examples of different chemical properties and
their drug classes. Dosing for neonatal circuits was based on
a standardized neonatal weight (3.5 kg), while for the other
systems, we have increased the dose in proportion to the rise
of volume to achieve similar theoretical concentrations.
We injected voriconazole 35 mg/40 mg/52.5 mg/68mg
(neonatal/infant/pediatric/adult) followed by vancomycin
45 mg/54 mg/67.5 mg/91.8mg through a line connected to the
tubing right after the reservoir bag (P1), with 5-s intervals in-
between injections. We flushed the line with 1ml of physiological
saline solution (0.9%) after voriconazole administration to avoid
crystallization or pooling effects.
Samples
A line attached to the tubing prior to the reservoir bag was used as
a pre-membrane (P2) sample-drawing site. For each system, we
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collected samples before a single-bolus drug administration (T0)
and during the circuit run at the following time intervals: 2 (T2),
10 (T10), 30 (T30), 180 (T180), 360 (T360) min, and 24 h (T24)
after injection. At T2, a control sample was collected and analyzed
at 24 h (T2-24) to determine spontaneous drug degradation.
The T2–24 samples were stored in ethylenediaminetetraacetate
(EDTA) sample tubes, which were maintained at the same
temperature as the tested systems until 24 h. For all other
samples (T0–T24), whole blood was collected in polypropylene
EDTA tubes and stored at 4◦C for a maximum of 12 h until
further processing. Afterward, all blood samples were centrifuged
(3,000 rounds/min for 6min), and the plasma supernatant
was transferred to labeled polypropylene cryogenic vials with
polyethylene screw caps (Nalgene Labware, Rochester, NY, USA).
Plasma samples were maintained at−80◦C until measurement.
Quantification of Drugs in Plasma Samples
Voriconazole and vancomycin were analyzed by means of
ultrafast liquid chromatography–mass spectrometry (LC-
MS/MS) in the pharmacy laboratory of Erasmus MC, as
previously described (30) with regard to voriconazole or a
validated immune-assay (Architect, Abbott) for vancomycin.
Methods were validated according to the US Food and
Drug Administration guidelines for bioanalytical method
validation (31).
Reference values are reported [including lower limit of
quantification (LLOQ) and upper limit of quantification
(ULOQ)]. Intra- and inter-assay means were within 15% of the
target range value, as requested by the FDA. For voriconazole,
the linear calibration range was 0.1–10 ng/ml. For vancomycin,
the linear calibration range was 0.6–50 mg/L.
Spontaneous Drug Degradation and
Expected Drug Levels
Spontaneous drug degradation was defined as the amount of drug
left after 24 h of spontaneous decay, and it was calculated as a
difference in drug recovery between T2 and T2–24. Expected
blood drug levels were calculated, accounting for the amount
of drug administered and the total circulating volume. Mean
recovery of each circuit category at 24 h was corrected by the
average drug spontaneous degradation.
Data Analysis
We performed a comparative evaluation of drug disposition
between four different ECMO circuits (MiniLung R© petite: MLP,
MiniLung R©: ML, iLAActivve R©: iLA, Xlung R©). We calculated the
average recovery corrected by spontaneous drug degradation at
2, 10, 30min and 3, 6, and 24 h across all circuit categories. The
trend over time is presented for the entire study period for each
drug (see Figures 1, 2). Data are expressed as mean (±SD) or
percentage. All analyses were performed using R version 3.4.3 (R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
In vitro ECMO models were maintained under physiological
conditions for 24 h. Throughout the experimental time, we did
not experience any circuit complications. A total of 72 samples
(eight for each circuit) were analyzed, in triplicate, for each drug.
All baseline plasma samples were free of study drugs.
The recovery of drugs after a 24-h exposure to the
extracorporeal circuit has been corrected for average drug
spontaneous degradation, and it is graphically reported in
Figures 1, 2. The mean percentage of drug recovery at 24 h was
20% for voriconazole and 62% for vancomycin. While the loss of
voriconazole was similar across all age circuits, vancomycin levels
decreased by 38% in theminiLung petite, by 25% in theminilung,
by 38% in the ILA active, and by 50% in the XLung circuits
(Table 1). Drug physicochemical properties, namely, lipophilicity
and protein binding, were derived from the Drug Bank online
database (32) and are summarized in Table 1.
DISCUSSION
Suboptimal antimicrobial exposure may be associated with
therapeutic failure, toxicity, antimicrobial resistance, and,
ultimately, worsened patient outcomes (2, 3). In this in
vitro study, we provide the equipment-related disposition
of voriconazole and vancomycin in contemporary ECMO
circuitry with iLAActivve, contributing insights into circuit-
and drug-specific determinants of PK changes during ECMO.
Voriconazole was largely sequestered in the circuits, with no
distinction across the different circuit sizes. Vancomycin was
absorbed slightly more in the neonatal (miniLung petite),
pediatric (ILA active), and adult (XLung) circuits than in the
infant ones (miniLung). Spontaneous drug decay over 24 h was
limited for both study drugs.
We consider these drugs as representative for the
pharmacological classes they belong to, thus extending the
relevance of our findings.
As expected, based on its lipophilicity and high protein
binding (32), voriconazole was largely sequestered in the systems,
uniformly across all size groups. Our data confirm those by
Mehta et al., who reported a dramatic loss of 60% of voriconazole
within 3 h from administration, in an ex vivo silicone membrane-
based model of blood primed circuit (33). Similarly, the altered
PK profile of voriconazole has been observed in pediatric and
adult case series (34, 35), showing a drop of voriconazole plasma
levels immediately after ECMO initiation or membrane change
(36). Higher initial loading and daily doses have been suggested,
with an intense therapeutic drug monitoring (TDM) to allow the
attainment of therapeutic serum concentrations (37).
Vancomycin is a hydrophilic and moderately protein-bound
agent and, given the narrow therapeutic window and the risk
of nephrotoxicity, its PK profile has been extensively evaluated
both in in vitro and in vivo settings (25–27). Indeed, targeting the
ratio of the area under the vancomycin concentration–time curve
over a 24-h period to the minimum inhibitory concentration
of the bacteria is crucial, especially among critically ill patients
(1, 38). Based on previous neonatal studies, vancomycin has
shown an increased volume of distribution (Vd) and a decreased
clearance (Cl) during ECMO, resulting in prolonged half-life
(25–27). However, these findings were related to older roller
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FIGURE 1 | Voriconazole: mean drug recovery (%) plotted vs. time (min) over 24 h for antimicrobial across the four different categories of systems tested: Minilung
petite (green), MiniLung (blue), iLaActivve (dark blue), and XLung (light blue).
FIGURE 2 | Vancomycin: mean drug recovery (%) plotted vs. time (min) over 24 h for antimicrobial across the four different categories of systems tested: Minilung
petite (green), MiniLung (blue), iLaActivve (dark blue), and XLung (light blue).
pump-based systems, whereas data on centrifugal pump-based
circuits are limited. In vitro studies on adult contemporary
circuits have revealed either steady vancomycin levels or
minimal loss over 24 and 48 h (22, 39). In contrast, we have
observed a substantial decay of vancomycin, especially within
the first 30min. These results are in line with our previous
in vitro findings on neonatal centrifugal-based circuits (18)
(Table 2). The discrepancy among these results may reflect the
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TABLE 1 | Mean drug recovery (mg/L; ±SD) after 24 h of circulation in the study testing circuits (r), corrected for spontaneous drug degradation compared to expected
drug levels (e).
Drug e-MLP r-MLP (n = 3) e-ML r-ML (n = 2) e-iLA r-iLA (n = 2) e-XL r-XL (n = 2) Spontaneous degradation LogP PB
VOR 140 24.9 (±3.5) 117.1 25 (±0.3) 134.7 26.3 (±0) 143.2 28.2 (±4.6) 0.8% 1.8 58
VAN 180 112 (±31.6) 177.1 133.2 (±49.7) 173.2 108.5 (±4,4) 193.7 96.5 (±13.5) 2.4% −3.1 50
iLA, iLAActivve®; MLP, MiniLung® petite; ML, MiniLung®; PB, protein binding; VAN, vancomycin; VOR, voriconazole; XL, Xlung®. LogP values and protein binding (PB) of study drugs
are derived from Drug Bank.
TABLE 2 | Comparison of mean drug recovery at 24 h (%) between centrifugal pump-based in vitro studies.
Current experiment Evidence from centrifugal-based systems Physico-chemical data
Drugs MLP
n = 3
ML
n = 2
iLA
n = 2
Xlung
n = 2
Spontaneous
drug
degradation
Medos n
Wildschut (18)
n = 2
180 min
Quadrox a
Shekar (22)
n = 4
24 h
Quadrox a
Lemaitre
(39) n = 3 24
h
LogP PB
%
Vd
L/kg
VOR 17 20 19 19 0.8 - - - 1.8 58 4.6
VAN 60 73 60 48 2.4 67.1* 90 100 −3.1 50 0.4–1
Volume (ml) 250 310 400 480 - 200 670 800
*Recovery at 180min. iLA, iLAActivve®; MLP, MiniLung® petite; ML, MiniLung®; PB, protein binding; VAN, vancomycin; Vd, volume of distribution, VOR, voriconazole, XL, Xlung®.
heterogeneity of experimental settings and highlights the need
for a better understanding of drug–circuit interactions, as new
materials and coatings become available. Amatched-cohort study
conducted in adult critically ill patients on ECMO receiving
continuous infusion of vancomycin showed comparable drug
concentrations between ECMO and non-ECMO patients (40).
Similarly, other clinical studies showed no PK differences of
vancomycin between ECMO adults and critically ill patients
not on ECMO (41, 42). The inconsistency between neonatal,
pediatric, and adult findings may originate from either ECMO
circuit-related factors or (patho-) physiological determinants, as
the priming fluid impacts more on neonatal circulating blood
volume compared to adults. Pending new data from pediatric
clinical PK of vancomycin, it is currently recommended to
increase the loading dose and to perform TDM, with target
trough plasma levels between 15 and 20µg/ml (24, 37, 43–
45).
Although spontaneous drug degradation was negligible
for both voriconazole and vancomycin, it is methodologically
rigorous to collect a dedicated sample on purpose, as the
degradation may be relevant for certain drugs undergoing
high spontaneous decay over time, such as midazolam
(30). Moreover, according to standard practice, we have
measured the total concentration of drugs, while in ECMO
patients, the detection of free drug concentration could be
worth exploring.
We acknowledge that our findings are not directly transferable
to the bedside for a number of reasons. The number of
circuits tested, which is limited by the high costs of the
equipment required, calls for caution when interpreting the
results to adapt the in vitro PK knowledge to clinical
practice. Owing to the ex vivo setting, patient- and disease-
related variables of drug disposition have not been taken
into account. However, exploring the impact of circuit-related
non-maturational covariates on antimicrobial PK variability
is suitable to inform the ECMO compartment within the
physiologically based PK modeling to develop a targeted dosing
regimen during ECMO (24). Given the dearth of data related
to antimicrobial drug disposition into contemporary ECMO
circuits, our findings might be valuable to fill this knowledge
gap in pharmacotherapy. Further efforts should be made to
integrate both preclinical and clinical evidence to optimize
pharmacotherapy in this vulnerable patient population by
taking into account different ECMO circuit types provided by
various manufacturers.
CONCLUSIONS
These results highlight the specific impact of contemporary
extracorporeal technology on antimicrobial therapy in critically
ill ECMO patients. Sequestration of voriconazole in newer
circuits was significant and similar to older silicone-based ones.
Although to a lesser extent than voriconazole, adsorption was
relevant for vancomycin. As suboptimal antibiotic therapy may
lead to treatment failure, maturational toxicity, and antimicrobial
resistance, TDM should be performed where available.
Meanwhile, further research is required to improve dosing
accuracy and move toward tailored pharmacotherapy with the
aim to deliver safe and effective ECMO management, across all
age groups.
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